GlassScriptPhysician profile
Hannah Lea Apple
NPI 1801437983
$3,900.92
in general payments reported to CMS, 2019-2025
27 companies · $1,026 in 2025
The $1,026 reported for 2025 was more than what 83% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $498 · 2022: $1,453 · 2023: $359 · 2024: $565 · 2025: $1,026.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,950.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,949.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,500.05 | 2021-2025 | |
| Alkermes, INC. | $466.57 | 2022-2025 | Aristada, Lybalvi, Vivitrol |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $409.24 | 2021-2023 | |
| Lilly USA, LLC | $387.47 | 2021-2025 | Mounjaro, Trulicity |
| Otsuka America Pharmaceutical, INC. | $370.91 | 2022-2025 | Rexulti, Abilify Asimtufii |
| Astrazeneca Pharmaceuticals LP | $83.95 | 2021-2024 | Farxiga |
| Pfizer INC. | $67.40 | 2021 | |
| Amgen INC. | $58.51 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $54.17 | 2023-2025 | Uzedy |
| Astellas Pharma US INC | $52.79 | 2025 | Veozah |
| Novartis Pharmaceuticals Corporation | $50.35 | 2022-2023 | |
| Lundbeck LLC | $48.94 | 2022-2025 | Rexulti |
| Novo Nordisk INC | $47.38 | 2021-2022 | |
| Exact Sciences Corporation | $41.30 | 2023-2024 | Cologuard Collection Kit |
| Biohaven Pharmaceutical Holding Company LTD. | $31.48 | 2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $28.56 | 2025 | Fanapt |
| Pharmacosmos Therapeutics INC. | $27.28 | 2025 | Monoferric |
| Organon LLC | $23.57 | 2021 | |
| Abbott Laboratories | $20.98 | 2021 | |
| Ucb, INC. | $17.52 | 2021 | |
| Insulet Corporation | $17.37 | 2021 | |
| Alk-Abello, INC | $17.29 | 2023 | Odactra, Grastek, Ragwitek |
| Supernus Pharmaceuticals, INC. | $17.21 | 2025 | Qelbree |
| Janssen Pharmaceuticals, INC | $15.92 | 2025 | Spravato |
| Currax Pharmaceuticals LLC | $15.77 | 2025 | Contrave |
| Allergan, INC. | $15.00 | 2021 | |
| Merck Sharp & Dohme LLC | $13.94 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hannah Apple listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.